- Atlas
- Medicine & Health
- Medical Oncology
Medical Oncology
Medical oncology is the branch of cancer medicine that treats cancer with drugs: chemicals that kill dividing cells, hormones that starve hormone-dependent tumors, antibodies and small molecules aimed at specific molecular targets, and treatments that turn the immune system against the cancer.
7 frameworks, from 1941 to today · Oncology · Medicine & Health
Overview
Medical oncology is the branch of cancer medicine that treats cancer with drugs: chemicals that kill dividing cells, hormones that starve hormone-dependent tumors, antibodies and small molecules aimed at specific molecular targets, and treatments that turn the immune system against the cancer12. Its practitioners are physicians who decide which drug or drug combination a patient should receive, at what dose, in what sequence, and alongside which surgery or radiation—and who manage the toxicity that follows. What is at stake is the central problem of cancer treatment: how to destroy a disease that is made of the patient's own cells, often already spread beyond the place it started, without killing the patient in the process. Medical oncology's history is the story of moving from poisons that happened to work, through combinations and preventive logic, to drugs designed against a specific molecular flaw and, most recently, against the immune system's own brakes.
Nitrogen Mustard and the Birth of Cytotoxic Chemotherapy
Before the 1940s, cancer was treated almost entirely locally—by surgery or radiation—and drug treatment of cancer barely existed. The change came from an unexpected direction: chemical warfare2. Mustard gas, used in the First World War, was known to damage bone marrow and lymphoid tissue. During the Second World War, the U.S. Office of Scientific Research and Development studied nitrogen mustards (related compounds) and found that they shrank lymphoid tumors in mice. In 1942, at Yale, the pharmacologists Louis Goodman and Alfred Gilman, working with the thoracic surgeon Gustaf Lindskog, gave a nitrogen mustard to a patient with advanced lymphoma; the tumor regressed, though only temporarily. The result was classified during the war and published in 19463.
The lesson was double-edged. A chemical could shrink a cancer—but the effect was brief, and the drug was a general poison to dividing cells. This is the defining property of cytotoxic chemotherapy: it kills cells that divide rapidly, which includes cancer cells but also bone marrow, gut lining, and hair follicles, which is why it causes low blood counts, nausea, and hair loss2. The first drugs were antifolates: aminopterin, used by Sidney Farber in Boston in 1948 to produce temporary remissions in childhood acute lymphoblastic leukemia, and its less toxic relative methotrexate. Farber's work, published in 1948, is often taken as the founding moment of modern chemotherapy—proof that a drug could drive a systemic childhood cancer into remission.
The Single-Agent Era and Its Limits
Through the 1950s, a growing list of cytotoxic drugs appeared, mostly by screening compounds for activity against fast-growing tumors. Alkylating agents such as cyclophosphamide, the antifolate methotrexate, the purine analog 6-mercaptopurine (used by Gertrude Elion and George Hitchings' group at Burroughs Wellcome), and later the plant alkaloid vincristine and the antibiotic doxorubicin. Each could shrink tumors; almost none could cure advanced disease. The problem was resistance: a tumor contains many cells, and some are less sensitive to any single drug, so they survive and regrow. The field also lacked a rigorous way to know whether a treatment actually helped. That changed with the rise of the randomized controlled trial—assigning patients by chance to treatment or control so that the comparison is fair—which became the standard method for evaluating cancer drugs in the decades after the Second World War.
Combination Chemotherapy and the First Cures
The decisive idea of the 1960s was to attack the tumor with several drugs at once, each with a different mechanism, so that a cell resistant to one would be killed by another4. The logic was worked out most influentially by Emil Frei, Emil Freireich, and colleagues at the National Cancer Institute, and by James Holland. In childhood acute lymphoblastic leukemia, combinations of drugs—vincristine, prednisone, methotrexate, and 6-mercaptopurine—produced sustained remissions where single agents had failed. The principle was generalized by the "log-kill" hypothesis of Howard Skipper and colleagues: a drug kills a constant fraction, not a constant number, of cancer cells, so repeated cycles are needed to reduce the tumor burden toward zero. Combination chemotherapy became the model, and by the 1970s it produced the first real cures of advanced cancer—notably in Hodgkin lymphoma (the MOPP regimen, developed by Vincent DeVita and colleagues at the NCI in the late 1960s) and in testicular cancer (the cisplatin-based regimen developed by Lawrence Einhorn at Indiana University in the mid-1970s). These were the field's proof of concept: disseminated cancer could, in some cases, be cured by drugs.
Adjuvant and Neoadjuvant Chemotherapy
If drugs could cure visible advanced disease, could they cure microscopic disease left behind after surgery? This is the idea of adjuvant chemotherapy: giving drugs after the primary tumor has been removed, to kill cells that have already spread but are too small to detect5. The landmark demonstration came in breast cancer5. The National Surgical Adjuvant Breast and Bowel Project (NSABP), led by Bernard Fisher, ran trials in the 1970s showing that adjuvant chemotherapy improved survival in women with node-positive breast cancer, and later that it helped node-negative patients too. The same logic was tested in colorectal cancer, where 5-fluorouracil-based adjuvant therapy became standard in the 1980s and 1990s. Neoadjuvant chemotherapy—given before surgery—followed, both to shrink tumors and to test a tumor's sensitivity to drugs. The adjuvant concept reframed cancer as often a systemic disease from the start, and it made the medical oncologist a partner in the treatment of patients who had already had surgery.
Hormonal Therapy
A parallel tradition treated cancers that depend on hormones. The prostate cancer work of Charles Huggins in the 1940s—showing that removing the testes or giving estrogen slowed advanced prostate cancer—won him a share of the 1966 Nobel Prize and established that some cancers are hormone-dependent. In breast cancer, the estrogen receptor was identified by Elwood Jensen in the late 1950s, and the drug tamoxifen, developed in the 1960s and 1970s, blocks estrogen's effect on breast tissue; large trials established it as adjuvant therapy for receptor-positive breast cancer. Later came aromatase inhibitors, which block estrogen production, and, for prostate cancer, drugs that suppress androgen signaling67. Hormonal therapy is the clearest early example of treating cancer by its biology rather than by indiscriminate toxicity6.
Molecularly Targeted Therapy
The next turning point was the idea that a drug could be aimed at the specific molecular abnormality that drives a cancer8. The founding case is chronic myeloid leukemia (CML), driven in most patients by the Philadelphia chromosome—a translocation that creates the BCR-ABL fusion gene, identified by Janet Rowley in 1973. The drug imatinib, developed by Brian Druker and colleagues and reported in 2001, inhibits the BCR-ABL protein and produced dramatic responses in CML. This was molecularly targeted therapy: a drug designed against a defined molecular target rather than against rapid cell division generally8. The approach spread—trastuzumab for HER2-amplified breast cancer (approved 1998), EGFR inhibitors in lung cancer, BRAF inhibitors in melanoma—and it changed how tumors were classified, since treatment now depended on the presence of a target, often detected by testing the tumor's tissue. Targeted drugs are generally less broadly toxic than cytotoxic chemotherapy, but resistance almost always emerges, because tumors acquire new mutations.
Cancer Immunotherapy
The oldest strand of immunotherapy is the idea of provoking the immune system against cancer. William Coley, in the 1890s, injected bacteria into tumors and reported occasional regressions—an approach long regarded with skepticism but now seen as an early hint that immune activation can matter. The modern era began with the recognition, by Lloyd Old and others in the 1960s and 1970s, of tumor antigens, and with the development of therapeutic antibodies. The decisive shift came with immune checkpoint inhibitors: antibodies that block the brakes the immune system uses to restrain itself9. The CTLA-4 checkpoint was targeted by ipilimumab, developed by James Allison and colleagues and approved in 2011 for melanoma; the PD-1/PD-L1 pathway was targeted by drugs such as pembrolizumab and nivolumab, approved from 2014. These drugs can produce durable responses in some patients with cancers previously considered untreatable, and they established immunotherapy as a pillar of cancer treatment alongside chemotherapy, targeted therapy, and radiation. A second major strand is CAR-T cell therapy, in which a patient's T cells are engineered to recognize a cancer antigen; it produced striking results in some blood cancers in the 2010s.
Where Medical Oncology Stands Today
Contemporary medical oncology works with all of these tools at once. Cytotoxic chemotherapy remains central, especially in combination regimens and in cancers without a defined target2. Hormonal therapy remains standard for receptor-positive breast and prostate cancer. Targeted therapy is guided by molecular testing of the tumor, and the field increasingly treats cancers by their molecular features rather than by their organ of origin. Immunotherapy is used across many cancer types, often in combination with other drugs. The randomized controlled trial remains the arbiter of whether a treatment helps, and the discipline of clinical trials methodology—with its phases, endpoints, and statistical rules—is what allows the field to distinguish a real benefit from a hopeful impression. The open questions are the ones the history has produced: why some patients respond to immunotherapy and most do not; how to anticipate and overcome resistance to targeted drugs; how to choose among combinations without exposing patients to unnecessary toxicity; and how to bring the benefits seen in trials to the full range of patients who need them.
References
- Oncology (Specialties), Wikipedia
- Chemotherapy (introduction, History), Wikipedia
- Alkylating antineoplastic agent (History), Wikipedia
- History of cancer chemotherapy (Combination chemotherapy), Wikipedia
- Adjuvant therapy (introduction, History), Wikipedia
- Hormonal therapy (oncology), Wikipedia
- Antiandrogen, Wikipedia
- Targeted therapy, Wikipedia
- Cancer immunotherapy, Wikipedia
The frameworks of Medical Oncology
Each framework is a way of working the field has used: when it held, and the question it answers.
- 1941-Present
- 1946-Present
- 1950-Present
Randomized Controlled Trials and Clinical Trial Methodology
How do we know a treatment truly works?
- 1965-Present
- 1972-Present
Adjuvant and Neoadjuvant Chemotherapy
Should drugs follow surgery to kill hidden cells?
- 1998-Present
- 2011-Present
How the ideas connect
Each arrow runs from an earlier idea to the later one it shaped. The list below says what passed between them.
Combination Chemotherapy grew out of Chemotherapy
Combination chemotherapy grew directly out of the single-agent cytotoxic era: Frei, Freireich and Holland built multi-drug regimens on the drugs and resistance problem left by single-agent chemotherapy, and Skipper's log-kill hypothesis formalized why repeated cycles of several agents were needed.
Carried by Emil Frei; Emil Freireich; Howard Skipper.
Adjuvant and Neoadjuvant Chemotherapy grew out of Combination Chemotherapy
Adjuvant chemotherapy applied the combination-chemotherapy principle to microscopic disease after surgery, taking the multi-drug regimens proven to cure advanced disease and giving them earlier in the disease course.
Carried by Bernard Fisher.
Targeted therapy influenced by Hormonal Therapy
Hormonal therapy established the principle of treating cancer by its biology rather than indiscriminate toxicity, and the estrogen receptor work of Elwood Jensen fed directly into the receptor-targeted logic of trastuzumab and later targeted drugs.
Carried by Elwood Jensen.
Adjuvant and Neoadjuvant Chemotherapy influenced by Chemotherapy
Adjuvant therapy took the cytotoxic drugs and the idea that drugs could eradicate disseminated cancer, then applied them to undetectable residual disease after surgery, as in 5-fluorouracil-based colorectal adjuvant therapy.
Targeted therapy reacted against Chemotherapy
Molecularly targeted therapy defined itself against the general cytotoxicity of chemotherapy, aiming at a specific molecular flaw such as BCR-ABL rather than at rapid cell division, with imatinib as the founding case.
Carried by Brian Druker.
Combination Chemotherapy influenced by Randomized Controlled Trials and Clinical Trial Methodology
The randomized controlled trial gave combination chemotherapy its method for proving that multi-drug regimens outperformed single agents, as in the leukemia trials of Frei and Freireich.
Carried by Emil Frei; Emil Freireich.
Adjuvant and Neoadjuvant Chemotherapy influenced by Randomized Controlled Trials and Clinical Trial Methodology
The adjuvant concept was established through randomized trials: Bernard Fisher's NSABP trials used randomized controlled methodology to show that chemotherapy after surgery improved survival in breast cancer.
Carried by Bernard Fisher; NSABP.
Targeted therapy influenced by Randomized Controlled Trials and Clinical Trial Methodology
Targeted drugs were validated through the randomized controlled trial methodology established in oncology, and tumor molecular testing became a new entry criterion for such trials.
Cancer Immunotherapy influenced by Targeted therapy
Checkpoint inhibitors are antibodies and small molecules aimed at defined molecular targets, so immunotherapy took the targeted-therapy toolkit and applied it to immune checkpoints such as CTLA-4 and PD-1.
Carried by James Allison.
Chemotherapy rival of Hormonal Therapy
Hormonal therapy and cytotoxic chemotherapy developed as parallel contemporaneous approaches to systemic cancer treatment, one exploiting hormone dependence and the other general cytotoxicity, competing for the same patients.
Carried by Charles Huggins.
Beyond the field
Where Medical Oncology's ideas came from in other fields, and what they led to there: the strongest 12 of 43 links.
Hormonal Therapy influenced by Hormone in Endocrinology And Diabetes
The isolation and chemical characterisation of steroid sex hormones in the 1920s-30s gave Huggins the agents and rationale for androgen deprivation in prostate cancer.
Carried by Charles Brenton Huggins.
Chemotherapy led to Combination chemotherapy in Hematology
The medical oncology chemotherapy tradition supplied the single agents and dosing concepts from which multi-drug regimens were assembled in the 1950s and 1960s.
Chemotherapy led to Combination Chemotherapy in Pediatric Hematology And Oncology
Combination chemotherapy grew directly out of single-agent cancer chemotherapy, extending the antimetabolite and alkylating agent work of the 1940s and 1950s into multi-drug regimens. The childhood leukemia trials of Frei and Freireich built on prior single-agent remissions to add drugs in combination.
Carried by Emil Frei; Emil Freireich.
Chemotherapy led to Combination Chemotherapy in Oncology
Combination chemotherapy grew directly out of single-agent cancer chemotherapy: the observation of resistance and partial responses to single drugs led to combining agents with different mechanisms, as in the MOPP regimen for Hodgkin's disease.
Chemotherapy influenced by Chemotherapy and the Magic Bullet in Medicinal Chemistry
Ehrlich's magic-bullet programme, with Salvarsan and later sulphonamide work, supplied the selective-toxicity concept that anticancer chemotherapy took up with nitrogen mustard and antifolates.
Carried by Paul Ehrlich.
Chemotherapy influenced by Chemotherapy and the Magic Bullet in Pharmaceutical Chemistry
The pharmaceutical-chemistry tradition of Ehrlich's magic bullet passed the idea of a drug selectively toxic to a target cell into anticancer drug development after the nitrogen mustard trials.
Carried by Paul Ehrlich.
Chemotherapy influenced by Magic-bullet chemotherapy in Drug Discovery
Magic-bullet chemotherapy of 1909-1945, built on Ehrlich's arsenicals and the sulphonamides, gave anticancer chemotherapy its founding aim of selective cytotoxicity.
Carried by Paul Ehrlich.
Randomized Controlled Trials and Clinical Trial Methodology led to Cooperative Group Trials in Pediatric Hematology And Oncology
Cooperative group trials are a direct application and extension of randomized controlled trial methodology to multi-institution cancer treatment comparisons. The statistical designs and randomization methods developed in clinical trial methodology were adopted by the leukemia and lymphoma cooperative groups.
Randomized Controlled Trials and Clinical Trial Methodology influenced Multidisciplinary Thoracic Oncology in Pulmonology
Randomized controlled trials and clinical trial methodology supplied the evidence base on which multidisciplinary thoracic oncology sequencing decisions rest. Landmark lung cancer trials comparing surgery, radiation and chemotherapy shaped the combined-modality standards the field adopted.
Combination Chemotherapy influenced by Chemotherapy in Oncology
Single-agent cancer chemotherapy, established with nitrogen mustard and antifolates from 1946, supplied the drugs and the resistance rationale from which multi-drug regimens were built.
Adjuvant and Neoadjuvant Chemotherapy influenced Multidisciplinary Tumor Board and Combined-Modality Sequencing in Surgical Oncology
Adjuvant and neoadjuvant chemotherapy, developed from the 1970s, created the need to sequence systemic treatment with surgery and radiation. This sequencing requirement drove the formation of multidisciplinary tumor boards and combined-modality protocols.
Adjuvant and Neoadjuvant Chemotherapy grew out of Combination Chemotherapy in Oncology
Adjuvant chemotherapy grew directly out of combination chemotherapy: regimens proven in advanced disease were moved into the post-surgical setting in the early 1970s breast cancer trials.

Medical Oncology is a planet in Nousfarer
Its city has a tower for each of these 7 frameworks. Land, walk in, and climb one concept at a time.
Land on Medical OncologyRelated fields
Fields its ideas are linked to
- Oncology 8 links
- Precision Oncology 5 links
- Gynecologic Oncology 4 links
- Pediatric Hematology And Oncology 4 links
- Medicinal Chemistry 3 links
- Immunotherapy 3 links
- Tumor Immunology 2 links
- Drug Discovery 2 links
- Impact Evaluation 1 link
- Epigenetics 1 link
- Endocrinology And Diabetes 1 link
- Hematology 1 link
More in Oncology
- Cancer Prevention And Screening
- Hematologic Malignancies
- Oncology
- Precision Oncology
- Radiation Oncology
- Surgical Oncology
See where Medical Oncology sits on the Map of Human Knowledge